Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid
Read More
Poster
The resources in this stream include various studies in cfDNA and ctDNA.
-
-
Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma
Read More
-
Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer
Read More
-
Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma
Read More
-
A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari
Read More
-
Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca
Read More
-
Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s
Read More
-
Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1
Read More
-
Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi
Read More
-
Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t
Read More
-
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j
Read More
-
Genomic alterations in early-onset versus average-onset stage IV colorectal cancer
Read More
-
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-ins
Read More
-
Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort
Read More
-
Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resista
Read More
-
Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine
Read More
-
PARPi response monitoring using personalized circulating tumor DNA testing in patients with ovarian cancer
Read More
-
Treatment Monitoring Utilizing ctDNA-based Molecular Residual Disease Detection in Early Stage Uterine Cancer
Read More
-
Utility of ctDNA as an Early Predictive Biomarker of Response to RT/CRT in Gynecologic Malignancies
Read More
-
Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian
Read More
-
Loading More...
